Immunohistochemical expression of MRP2 and clinical resistance to platinum-based chemotherapy in small cell lung cancer

Rie Ushijima, Koichi Takayama, Miiru Izumi, Taishi Harada, Yasuhiro Horiuchi, Junji Uchino, Nobuyuki Hara, Yoichi Nakanishi

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Determining an effective predictor of clinical drug resistance in small cell lung cancer (SCLC) is considered to be important. In this study, the relationship between the expression of P-glycoprotein (P-gp), multidrug resistance-associated protein 1 (MRP1) and MRP2, which are the members of ATP-binding cassette superfamily transporter, and of the p53 tumor suppressor gene and the response to chemotherapy were analysed. The expression of P-gp, MRP1, MRP2, and p53 was determined by an immunohistochemical analysis of transbronchial biopsy (TBB) specimens from 61 SCLC patients. The relationship of such expression was also investigated regarding chemotherapy and clinicopathological factors. The response rate in the MRP2-negative group was significantly higher than that in the MRP2-positive group (88% versus 50%). The P-gp-negative group responded significantly better to chemotherapy than the P-gp-positive group, with a response rate of 81% versus 39%. No relationship could be found between the response to chemotherapy and immunostaining for MRP1 or p53. In 37 patients treated with platinum-based chemotherapy, the response rate of patients in the MRP2-negative group was significantly higher than that in the positive group (92% versus 50%). In a multiple logistic regression analysis, MRP2 as well as P-gp were shown to be statistically significant predictors of chemotherapy resistance. These results suggest that immunostaining of MRP2 for TBB specimens may help to predict clinical resistance to platinum agents. This is the first report which indicates that the immunohistochemical expression of MRP2 is positively related to a clinical resistance to platinum.

Original languageEnglish
Pages (from-to)4351-4358
Number of pages8
JournalAnticancer Research
Volume27
Issue number6 C
Publication statusPublished - Nov 2007

Fingerprint

Small Cell Lung Carcinoma
Platinum
P-Glycoprotein
Drug Therapy
Biopsy
ATP-Binding Cassette Transporters
Tumor Suppressor Genes
Drug Resistance
Logistic Models
Regression Analysis
multidrug resistance-associated protein 1

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Ushijima, R., Takayama, K., Izumi, M., Harada, T., Horiuchi, Y., Uchino, J., ... Nakanishi, Y. (2007). Immunohistochemical expression of MRP2 and clinical resistance to platinum-based chemotherapy in small cell lung cancer. Anticancer Research, 27(6 C), 4351-4358.

Immunohistochemical expression of MRP2 and clinical resistance to platinum-based chemotherapy in small cell lung cancer. / Ushijima, Rie; Takayama, Koichi; Izumi, Miiru; Harada, Taishi; Horiuchi, Yasuhiro; Uchino, Junji; Hara, Nobuyuki; Nakanishi, Yoichi.

In: Anticancer Research, Vol. 27, No. 6 C, 11.2007, p. 4351-4358.

Research output: Contribution to journalArticle

Ushijima, R, Takayama, K, Izumi, M, Harada, T, Horiuchi, Y, Uchino, J, Hara, N & Nakanishi, Y 2007, 'Immunohistochemical expression of MRP2 and clinical resistance to platinum-based chemotherapy in small cell lung cancer', Anticancer Research, vol. 27, no. 6 C, pp. 4351-4358.
Ushijima R, Takayama K, Izumi M, Harada T, Horiuchi Y, Uchino J et al. Immunohistochemical expression of MRP2 and clinical resistance to platinum-based chemotherapy in small cell lung cancer. Anticancer Research. 2007 Nov;27(6 C):4351-4358.
Ushijima, Rie ; Takayama, Koichi ; Izumi, Miiru ; Harada, Taishi ; Horiuchi, Yasuhiro ; Uchino, Junji ; Hara, Nobuyuki ; Nakanishi, Yoichi. / Immunohistochemical expression of MRP2 and clinical resistance to platinum-based chemotherapy in small cell lung cancer. In: Anticancer Research. 2007 ; Vol. 27, No. 6 C. pp. 4351-4358.
@article{3fa88fc5778a483998e751c00509b30e,
title = "Immunohistochemical expression of MRP2 and clinical resistance to platinum-based chemotherapy in small cell lung cancer",
abstract = "Determining an effective predictor of clinical drug resistance in small cell lung cancer (SCLC) is considered to be important. In this study, the relationship between the expression of P-glycoprotein (P-gp), multidrug resistance-associated protein 1 (MRP1) and MRP2, which are the members of ATP-binding cassette superfamily transporter, and of the p53 tumor suppressor gene and the response to chemotherapy were analysed. The expression of P-gp, MRP1, MRP2, and p53 was determined by an immunohistochemical analysis of transbronchial biopsy (TBB) specimens from 61 SCLC patients. The relationship of such expression was also investigated regarding chemotherapy and clinicopathological factors. The response rate in the MRP2-negative group was significantly higher than that in the MRP2-positive group (88{\%} versus 50{\%}). The P-gp-negative group responded significantly better to chemotherapy than the P-gp-positive group, with a response rate of 81{\%} versus 39{\%}. No relationship could be found between the response to chemotherapy and immunostaining for MRP1 or p53. In 37 patients treated with platinum-based chemotherapy, the response rate of patients in the MRP2-negative group was significantly higher than that in the positive group (92{\%} versus 50{\%}). In a multiple logistic regression analysis, MRP2 as well as P-gp were shown to be statistically significant predictors of chemotherapy resistance. These results suggest that immunostaining of MRP2 for TBB specimens may help to predict clinical resistance to platinum agents. This is the first report which indicates that the immunohistochemical expression of MRP2 is positively related to a clinical resistance to platinum.",
author = "Rie Ushijima and Koichi Takayama and Miiru Izumi and Taishi Harada and Yasuhiro Horiuchi and Junji Uchino and Nobuyuki Hara and Yoichi Nakanishi",
year = "2007",
month = "11",
language = "English",
volume = "27",
pages = "4351--4358",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6 C",

}

TY - JOUR

T1 - Immunohistochemical expression of MRP2 and clinical resistance to platinum-based chemotherapy in small cell lung cancer

AU - Ushijima, Rie

AU - Takayama, Koichi

AU - Izumi, Miiru

AU - Harada, Taishi

AU - Horiuchi, Yasuhiro

AU - Uchino, Junji

AU - Hara, Nobuyuki

AU - Nakanishi, Yoichi

PY - 2007/11

Y1 - 2007/11

N2 - Determining an effective predictor of clinical drug resistance in small cell lung cancer (SCLC) is considered to be important. In this study, the relationship between the expression of P-glycoprotein (P-gp), multidrug resistance-associated protein 1 (MRP1) and MRP2, which are the members of ATP-binding cassette superfamily transporter, and of the p53 tumor suppressor gene and the response to chemotherapy were analysed. The expression of P-gp, MRP1, MRP2, and p53 was determined by an immunohistochemical analysis of transbronchial biopsy (TBB) specimens from 61 SCLC patients. The relationship of such expression was also investigated regarding chemotherapy and clinicopathological factors. The response rate in the MRP2-negative group was significantly higher than that in the MRP2-positive group (88% versus 50%). The P-gp-negative group responded significantly better to chemotherapy than the P-gp-positive group, with a response rate of 81% versus 39%. No relationship could be found between the response to chemotherapy and immunostaining for MRP1 or p53. In 37 patients treated with platinum-based chemotherapy, the response rate of patients in the MRP2-negative group was significantly higher than that in the positive group (92% versus 50%). In a multiple logistic regression analysis, MRP2 as well as P-gp were shown to be statistically significant predictors of chemotherapy resistance. These results suggest that immunostaining of MRP2 for TBB specimens may help to predict clinical resistance to platinum agents. This is the first report which indicates that the immunohistochemical expression of MRP2 is positively related to a clinical resistance to platinum.

AB - Determining an effective predictor of clinical drug resistance in small cell lung cancer (SCLC) is considered to be important. In this study, the relationship between the expression of P-glycoprotein (P-gp), multidrug resistance-associated protein 1 (MRP1) and MRP2, which are the members of ATP-binding cassette superfamily transporter, and of the p53 tumor suppressor gene and the response to chemotherapy were analysed. The expression of P-gp, MRP1, MRP2, and p53 was determined by an immunohistochemical analysis of transbronchial biopsy (TBB) specimens from 61 SCLC patients. The relationship of such expression was also investigated regarding chemotherapy and clinicopathological factors. The response rate in the MRP2-negative group was significantly higher than that in the MRP2-positive group (88% versus 50%). The P-gp-negative group responded significantly better to chemotherapy than the P-gp-positive group, with a response rate of 81% versus 39%. No relationship could be found between the response to chemotherapy and immunostaining for MRP1 or p53. In 37 patients treated with platinum-based chemotherapy, the response rate of patients in the MRP2-negative group was significantly higher than that in the positive group (92% versus 50%). In a multiple logistic regression analysis, MRP2 as well as P-gp were shown to be statistically significant predictors of chemotherapy resistance. These results suggest that immunostaining of MRP2 for TBB specimens may help to predict clinical resistance to platinum agents. This is the first report which indicates that the immunohistochemical expression of MRP2 is positively related to a clinical resistance to platinum.

UR - http://www.scopus.com/inward/record.url?scp=37549053600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549053600&partnerID=8YFLogxK

M3 - Article

C2 - 18214043

AN - SCOPUS:37549053600

VL - 27

SP - 4351

EP - 4358

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6 C

ER -